Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
2000 1
2002 1
2003 1
2004 3
2005 4
2006 3
2007 3
2008 9
2009 9
2010 11
2011 3
2012 1
2013 4
2014 5
2015 12
2016 9
2017 6
2018 7
2019 8
2020 5
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

92 results
Results by year
Filters applied: . Clear all
Page 1
Patient-derived xenograft (PDX) models in basic and translational breast cancer research.
Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT. Dobrolecki LE, et al. Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x. Cancer Metastasis Rev. 2016. PMID: 28025748 Free PMC article. Review.
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.
Fu X, Pereira R, De Angelis C, Veeraraghavan J, Nanda S, Qin L, Cataldo ML, Sethunath V, Mehravaran S, Gutierrez C, Chamness GC, Feng Q, O'Malley BW, Selenica P, Weigelt B, Reis-Filho JS, Cohen O, Wagle N, Nardone A, Jeselsohn R, Brown M, Rimawi MF, Osborne CK, Schiff R. Fu X, et al. Proc Natl Acad Sci U S A. 2019 Dec 11;116(52):26823-34. doi: 10.1073/pnas.1911584116. Online ahead of print. Proc Natl Acad Sci U S A. 2019. PMID: 31826955 Free PMC article.
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.
Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF. Prat A, et al. J Natl Cancer Inst. 2020 Jan 1;112(1):46-54. doi: 10.1093/jnci/djz042. J Natl Cancer Inst. 2020. PMID: 31037288 Free PMC article.
Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance.
Bi M, Zhang Z, Jiang YZ, Xue P, Wang H, Lai Z, Fu X, De Angelis C, Gong Y, Gao Z, Ruan J, Jin VX, Marangoni E, Montaudon E, Glass CK, Li W, Huang TH, Shao ZM, Schiff R, Chen L, Liu Z. Bi M, et al. Nat Cell Biol. 2020 Jun;22(6):701-715. doi: 10.1038/s41556-020-0514-z. Epub 2020 May 18. Nat Cell Biol. 2020. PMID: 32424275 Free PMC article.
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.
De Angelis C, Nagi C, Hoyt CC, Liu L, Roman K, Wang C, Zheng Y, Veeraraghavan J, Sethunath V, Nuciforo P, Wang T, Tsimelzon A, Mao S, Hilsenbeck SG, Trivedi MV, Cataldo ML, Pavlick A, Wolff AC, Weigelt B, Reis-Filho JS, Prat A, Gutierrez C, Osborne CK, Rimawi MF, Schiff R. De Angelis C, et al. Clin Cancer Res. 2020 Feb 1;26(3):738-745. doi: 10.1158/1078-0432.CCR-19-1402. Epub 2019 Oct 25. Clin Cancer Res. 2020. PMID: 31653641 Free PMC article. Clinical Trial.
The changing role of ER in endocrine resistance.
Nardone A, De Angelis C, Trivedi MV, Osborne CK, Schiff R. Nardone A, et al. Breast. 2015 Nov;24 Suppl 2(0 2):S60-6. doi: 10.1016/j.breast.2015.07.015. Epub 2015 Aug 10. Breast. 2015. PMID: 26271713 Free PMC article. Review.
92 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page